JP Morgan Chase’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,944
| Closed | -$38.1K | – | 7889 |
|
|
2024
Q4 | $38.1K | Buy |
1,944
+1,764
| +980% | +$32.8K | ﹤0.01% | 6102 |
|
|
2024
Q3 | $2.82K | Buy |
180
+160
| +800% | +$1.42K | ﹤0.01% | 6574 |
|
|
2024
Q2 | $169 | Sell |
20
-1,274
| -98% | -$14.9K | ﹤0.01% | 6809 |
|
|
2024
Q1 | $20K | Sell |
1,294
-432
| -25% | -$6.59K | ﹤0.01% | 6226 |
|
|
2023
Q4 | $23.8K | Sell |
1,726
-324
| -16% | -$3.83K | ﹤0.01% | 6211 |
|
|
2023
Q3 | $23.4K | Sell |
2,050
-525
| -20% | -$9.75K | ﹤0.01% | 6030 |
|
|
2023
Q2 | $64.1K | Sell |
2,575
-1,719
| -40% | -$50.4K | ﹤0.01% | 5649 |
|
|
2023
Q1 | $156K | Buy |
4,294
+1,244
| +41% | +$76.2K | ﹤0.01% | 5208 |
|
|
2022
Q4 | $184K | Sell |
3,050
-463
| -13% | -$31K | ﹤0.01% | 5081 |
|
|
2022
Q3 | $264K | Sell |
3,513
-812
| -19% | -$84.8K | ﹤0.01% | 4814 |
|
|
2022
Q2 | $496K | Sell |
4,325
-1,254
| -22% | -$147K | ﹤0.01% | 4554 |
|
|
2022
Q1 | $1.06M | Sell |
5,579
-21,486
| -79% | -$4.97M | ﹤0.01% | 4225 |
|
|
2021
Q4 | $9.38M | Buy |
27,065
+21,258
| +366% | +$8.24M | ﹤0.01% | 2508 |
|
|
2021
Q3 | $1.95M | Buy |
5,807
+5,805
| +290,250% | +$2.98M | ﹤0.01% | 3814 |
|
|
2021
Q2 | $2K | Buy |
+2
| New | +$1.55K | ﹤0.01% | 6222 |
|
JP Morgan Chase's OMIC Position: Q1 2025 in Review
JP Morgan Chase sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 1,944 shares — an estimated $38.1K sold.
JP Morgan Chase first reported a position in OMIC in Q2 2021 and held it in 15 quarters. The position peaked at $9.38M in Q4 2021. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- JP Morgan Chase reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- JP Morgan Chase sold 1,944 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $38.1K.
- JP Morgan Chase first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- JP Morgan Chase's Singular Genomics Systems, Inc. Common Stock position peaked at $9.38M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.